Funder: National Institutes of Health

Due Dates: March 13, 2025 (AIDS) | December 4, 2025 (AIDS) | March 13, 2026 (AIDS) | December 4, 2026 (AIDS)

Funding Amounts: Up to $225,000 in direct costs for a 1-year project; 2–3 awards anticipated per cycle.

Summary: Supports planning and development of a comprehensive product development strategy for next-generation HIV treatments, comorbidities, and prevention, enabling IND submission to the FDA.

Key Information: Clinical trials are not allowed; limited to planning and strategy activities for IND-enabling work.